Sérum pour cils avec Bimatoprost: Effets, sécurité et alternatives

• What is bimatoprost
• How does an eyelash serum with bimatoprost work
• Why is the safety of bimatoprost sometimes questioned
• What does science say
• Which serums contain bimatoprost
• Ecuri Superlash: The Best Alternative without bimatoprost

Le bimatoprost est un analogue synthétique de la prostaglandine développé à l'origine comme médicament contre le glaucome (augmentation de la pression oculaire). Au cours des essais cliniques, les chercheurs ont constaté que les patients avaient comme effet secondaire des cils sensiblement plus longs et plus fournis (Smith et al., 2009). Cela a conduit à l'application cosmétique du bimatoprost dans les sérums pour cils, comme la marque bien connue Latisse, qui, en 2008, a été la première à être approuvée par la FDA pour la croissance des cils (FDA, 2008).

Bimatoprost stimulates the anagen phase of the eyelash cycle – this is the active growth phase. This causes the eyelashes to grow:

• Longer because the growth phase is extended;
• Thicker because more hairs are in the growth phase at the same time;
• Darker due to increased pigment production.

The first visible results often appear after 4 to 8 weeks, with maximum effect after approximately 12 to 16 weeks (Glaser & Jones, 2010).

It is often claimed that bimatoprost is unsafe for cosmetic use. The most commonly cited concerns are:

• Discoloration of the skin around the eyes (periorbital hyperpigmentation)
• Eye irritation or itching
• Changes in iris color with prolonged use

However, these side effects are very rare and mainly occur with incorrect use or overdose. Many of these claims are based on experiences with eye drops (such as Lumigan), where the product is applied inside the eye – in contrast to the correct application of eyelash serum on the skin above the lash line (Chien et al., 2015).

Multiple clinical studies have confirmed the effectiveness and safety of bimatoprost as an eyelash enhancer:

• A large-scale study published in the Journal of the American Academy of Dermatology (Glaser & Jones, 2010) showed a significant increase in eyelash length, thickness, and color without serious side effects when used correctly.
• According to Smith et al. (2009), the effects of prostaglandin analogues on hair growth are convincing, and their cosmetic applications are well tolerated when used topically.
• The FDA approved Latisse in 2008 based on strictly controlled clinical data demonstrating its safety and effectiveness (FDA, 2008).
• A review article in the American Journal of Clinical Dermatology states that side effects are mainly mild and temporary, provided that the instructions are strictly followed (Chien et al., 2015).
• The conclusion? Bimatoprost is safe when used correctly and can produce impressive results (Abdelmaksoud et al., 2018).

The irony here is that bimatoprost is virtually the only ingredient considered to be an active substance in eyelash serums that has actually been tested and researched in the literature. So, any website can claim that other substances such as peptides, botanical extracts, and even other prostaglandin analogues are safe (or safer), but the fact remains that the only substance that has been thoroughly researched in the literature in terms of safety for eyelash lengthening is bimatoprost.

Although Latisse is the best-known brand, there are other eyelash serums containing bimatoprost or related prostaglandin analogues available. Some examples are:

• Careprost (India) – Widely used as an alternative to Latisse.
• Latisse – Premier médicament approuvé par la FDA contre les cils courts.
• Lumigan (off-label use) – Originally for glaucoma, but used as an eyelash serum.
• Old Kruidvat Superlash formula – Contained bimatoprost but has been taken off the shelves for several years

However, in many European countries, bimatoprost is only available on prescription, which limits its availability.

Are you looking for a safe and effective alternative to an eyelash serum containing bimatoprost? Then Ecuri Superlash is an excellent choice.

Why Ecuri Superlash?

• Free from bimatoprost (contains a prostaglandin analogue as an alternative)
• Contains natural peptides and growth factors
• Suitable for daily use, even for sensitive eyes
• Visible results within 4-6 weeks
• Safe, even with prolonged use

Ecuri Superlash stimulates eyelash growth in a gentle, skin-friendly way – with peptides, growth factors, and a prostaglandin analogue working together for maximum results. This makes it ideal for people who want beautiful results without the possible side effects of bimatoprost.

Un sérum pour cils contenant du bimatoprost est un moyen puissant et éprouvé de rendre vos cils plus fournis et plus longs. Bien qu'il y ait des idées fausses sur son innocuité, la recherche scientifique montre que lorsqu'il est utilisé correctement, il s'agit d'un produit cosmétique efficace et sûr.

Vous préférez une alternative sans prostaglandines ? Dans ce cas, Ecuri Superlash vous est vivement recommandé. Vous pourrez ainsi profiter de beaux cils - de manière naturelle et sûre.

1. Smith, S., Fagien, S., Whitcup, S. M., & Swann, S. (2009). Prostaglandin analog effects on hair growth: A review and clinical applications. Dermatologic Surgery, 35(8), 1287–1300. https://doi.org/10.1111/j.1524-4725.2009.01226.x
2. Glaser, D. A., & Jones, D. (2010). Efficacy and safety of bimatoprost in the treatment of hypotrichosis of the eyelashes. Journal of the American Academy of Dermatology, 62(6), 1013–1027. https://doi.org/10.1016/j.jaad.2009.07.025
3. U.S. Food and Drug Administration (FDA). (2008). FDA Approves Latisse to Grow Eyelashes. https://www.fda.gov/news-events/press-announcements/fda-approves-latisse-grow-eyelashes
4. Abdelmaksoud, A., et al. (2018). Bimatoprost in dermatology: Beyond glaucoma. Journal of Dermatological Treatment, 29(2), 142–148. https://doi.org/10.1080/09546634.2017.1343259
5. Chien, A. L., Qi, J., & Cohen, B. A. (2015). Use of prostaglandin analogs in dermatology: An evidence-based review. American Journal of Clinical Dermatology, 16(5), 445–460. https://doi.org/10.1007/s40257-015-0147-7